RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine the highest dose of lenalidomide and
RAD001 that can be given without causing too many serious side effects. Another goal of this
research study is to look at how the participants cancer may respond to the study treatment.
Additionally, we wish to learn more about how the body breaks down and gets rid of the study
drugs. We will also try to find substances in the blood (biomarkers) that may help predict
how myeloma will respond to study treatment.
Phase:
Phase 1
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Brigham and Women's Hospital Dana-Farber Cancer Institute Mayo Clinic Medical College of Wisconsin Memorial Sloan Kettering Cancer Center